
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen is well-positioned in the peripheral nerve repair market with its innovative products and strong clinical data supporting their efficacy. With the recent FDA approval of their Avance Nerve Graft, Axogen is now able to target even more patients in need of peripheral nerve repair. The company's strong financial performance, with a 27% year-over-year revenue growth in the first quarter of 2026, and a positive outlook for future revenue growth, make it an attractive investment opportunity.
Bears say
Axogen is showing promising signs of increased revenue growth, with a projected 20% year-over-year increase in FY26 and continued growth potential through 2028. However, recent product cost pressure and the uncertainty of potential payer coverage rulings may hinder profitability in the near future. Despite management's commitment to positive free cash flow for the year, the company's financials may need to be closely monitored as these factors could impact their long-term growth strategy.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares